<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074291</url>
  </required_header>
  <id_info>
    <org_study_id>441/2019/Oss/IOR</org_study_id>
    <nct_id>NCT04074291</nct_id>
  </id_info>
  <brief_title>Cross Cultural Validation of the Italian Version of the Bt-DUX</brief_title>
  <official_title>Cross Cultural Validation of the Italian Version of the Bt-DUX: A Subjective Measure of Health Related Quality of Life in Patients Who Underwent Surgery for Lower Extremity Malignant Bone Tumour</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the presented study is to translate the English Bt-DUX (Bt-DUX-Eng)
      questionnaire into the Italian language and then examine the validity of the Italian version
      of the Bt-DUX (Bt-DUX-It).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Validation of the Italian Bt-DUX:

      Cross sectional study among patients of the Istituto Ortopedico Rizzoli, Bologna, Italy, will
      carry out. All patients who underwent a surgical intervention due to a malignant bone tumour
      in the leg will be identified through hospital records and a survey consisting of different
      QoL questionnaires will be executed:

      Bt-DUX, EORTC QLQ C-30, The Toronto Extremity Salvage Score (TESS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bt-DUX.it</measure>
    <time_frame>Between 12 and 60 months after the surgery</time_frame>
    <description>The disease specific Bt-DUX relates to the patient's subjective feeling about a specific aspect, using abstract faces (smiley's) as answer categories. The expressions from very happy to sad (score 1-5) form a five-point Likert scale. The Bt-DUX consists of 20 questions which cover the domains social, emotional, cosmetical and physical functioning. Single item scores were recoded and computed into raw total and domain scores. These raw scores were converted into total and domain scores, ranging from 0-100, with the highest scores indicating better QoL .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Toronto Extremity Salvage Score (TESS)</measure>
    <time_frame>Between 12 and 60 months after the surgery</time_frame>
    <description>The Toronto Extremity Salvage Score (TESS), a validated and reliable disease-specific measure developed to evaluate physical disability in patients treated for extremity sarcoma. The self-administered questionnaire includes 30 items on activity limitations in daily life, such as restrictions in body movement, mobility, self-care and performance of daily tasks and routine. The degree of physical disability is rated from 0 (not possible) to 5 (without any problem). The raw score is converted to a score ranged from 0 to 100 points, with higher scores indicating no functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ (Quality of Life Questionnaire) C-30.</measure>
    <time_frame>Between 12 and 60 months after the surgery</time_frame>
    <description>The 30-item EORTC QLQ-C30 questionnaire is composed of scales that evaluate physical functioning and role functioning, as well as emotional, social, and cognitive functioning and global QOL. Three symptom scales measure fatigue, pain, and emesis, while six single items assess financial impact and physical symptoms such as dyspnoea, sleep disturbance, appetite, diarrhoea, and constipation. The time frame is the past week. The questions are formatted with either yes or no answers, or by using four-answer categories that range from 1, not at all, to 4, very much. The two questions on general health and global QOL are to be answered on a numbered visual-analogue scale from I to 7.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Quality of Life</condition>
  <condition>Bone Neoplasm</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who underwent a surgical intervention due to a malignant bone tumour in the
        leg will be identified through hospital records of Istituto Ortopedico Rizzoli.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients are eligible if they're aged between 15 and 25 years at the time of the
             selection, if the time since surgery is ranged between 12 and 60 months, if the
             malignant bone tumour (osteosarcoma or Ewing's sarcoma) was located around the hip or
             the knee and the surgical intervention consisted of limb sparing or ablative surgery.

        Exclusion Criteria:

          -  Patients will be excluded if other medical conditions limit their physical activities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Cristiana Forni</last_name>
    <role>Study Chair</role>
    <affiliation>Isituto Ortopedico Rizzoli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mattia Morri</last_name>
    <phone>0516366354</phone>
    <email>mattia.morri@ior.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattia Morri, PT</last_name>
      <phone>0516366694</phone>
      <phone_ext>0039</phone_ext>
      <email>mattia.morri@ior.it</email>
    </contact>
    <contact_backup>
      <last_name>Cristiana Forni, RN</last_name>
      <phone>0516366694</phone>
      <phone_ext>0039</phone_ext>
      <email>cristiana.forni@ior.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Bekkering WP, Vlieland TP, Koopman HM, Schaap GR, Schreuder HW, Beishuizen A, Tissing WJ, Hoogerbrugge PM, Anninga JK, Taminiau AH. The Bt-DUX: development of a subjective measure of health-related quality of life in patients who underwent surgery for lower extremity malignant bone tumor. Pediatr Blood Cancer. 2009 Sep;53(3):348-55. doi: 10.1002/pbc.22078.</citation>
    <PMID>19459200</PMID>
  </reference>
  <reference>
    <citation>Bekkering WP, Billing L, Grimer RJ, Vlieland TP, Koopman HM, Nelissen RG, Taminiau AH. Translation and preliminary validation of the English version of the DUX questionnaire for lower extremity bone tumor patients (Bt-DUX): a disease-specific measure for quality of life. J Surg Oncol. 2013 Mar;107(4):353-9. doi: 10.1002/jso.23218. Epub 2012 Jul 17.</citation>
    <PMID>22806913</PMID>
  </reference>
  <reference>
    <citation>Davis AM, Wright JG, Williams JI, Bombardier C, Griffin A, Bell RS. Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual Life Res. 1996 Oct;5(5):508-16.</citation>
    <PMID>8973131</PMID>
  </reference>
  <reference>
    <citation>Apolone G, Filiberti A, Cifani S, Ruggiata R, Mosconi P. Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients. Ann Oncol. 1998 May;9(5):549-57.</citation>
    <PMID>9653497</PMID>
  </reference>
  <reference>
    <citation>van Doorn RK, Winkler LM, Zwinderman KH, Mearin ML, Koopman HM. CDDUX: a disease-specific health-related quality-of-life questionnaire for children with celiac disease. J Pediatr Gastroenterol Nutr. 2008 Aug;47(2):147-52. doi: 10.1097/MPG.0b013e31815ef87d.</citation>
    <PMID>18664865</PMID>
  </reference>
  <reference>
    <citation>Vrijmoet-Wiersma CM, Kooloos VM, Koopman HM, Kolk AM, van der Laan I, Grootenhuis MA, Egeler RM. Health-related quality of life, cognitive functioning and behaviour problems in children with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Jan;52(1):116-22. doi: 10.1002/pbc.21740.</citation>
    <PMID>18819122</PMID>
  </reference>
  <reference>
    <citation>Bekkering WP, Vliet Vlieland TP, Koopman HM, Schaap GR, Beishuizen A, Anninga JK, Wolterbeek R, Nelissen RG, Taminiau AH. A prospective study on quality of life and functional outcome in children and adolescents after malignant bone tumor surgery. Pediatr Blood Cancer. 2012 Jun;58(6):978-85. doi: 10.1002/pbc.23328. Epub 2011 Oct 11.</citation>
    <PMID>21990185</PMID>
  </reference>
  <reference>
    <citation>Bekkering WP, Vliet Vlieland TP, Fiocco M, Koopman HM, Schoones JW, Nelissen RG, Taminiau AH. Quality of life, functional ability and physical activity after different surgical interventions for bone cancer of the leg: A systematic review. Surg Oncol. 2012 Jun;21(2):e39-47. doi: 10.1016/j.suronc.2011.09.002. Epub 2011 Oct 4. Review.</citation>
    <PMID>21974808</PMID>
  </reference>
  <reference>
    <citation>Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000 Dec 15;25(24):3186-91. Review.</citation>
    <PMID>11124735</PMID>
  </reference>
  <reference>
    <citation>Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993 Dec;46(12):1417-32. Review.</citation>
    <PMID>8263569</PMID>
  </reference>
  <reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.</citation>
    <PMID>8433390</PMID>
  </reference>
  <reference>
    <citation>Koopman HM, Koetsier JA, Taminiau AH, Hijnen KE, Bresters D, Egeler RM. Health-related quality of life and coping strategies of children after treatment of a malignant bone tumor: a 5-year follow-up study. Pediatr Blood Cancer. 2005 Oct 15;45(5):694-9.</citation>
    <PMID>15924359</PMID>
  </reference>
  <reference>
    <citation>Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007 Jan;60(1):34-42. Epub 2006 Aug 24.</citation>
    <PMID>17161752</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT04074291/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

